Ad-hoc News

As part of the current capital increase MOLOGEN AG has achieved gross proceeds of 22 million EUR. Overall, 2,589,819 new shares have been placed at an issue price of 8.50 EUR. Existing investors contributed in a significant amount to the capital...

MOLOGEN AG (ISIN: DE0006637200) has today set the subscription price for the new shares that are being offered as part of the rights offering of up to 3,189,819 new shares in the company from the authorized capital 2011.
These are being...

The management board of MOLOGEN AG (ISIN: DE0006637200) has today resolved with the consent of the supervisory board to execute a capital increase with a rights offering to the shareholders. In accordance with Section 4, paragraph 3 of the bylaws,...

The biotechnology company MOLOGEN AG has conducted an initial assessment of the phase 2 colorectal cancer study with MGN1703. The assessment of 55 patients showed that the primary endpoint, the prolongation of the median progression-free survival,...

In a further evaluation of the phase I/II renal cancer study with MGN1601, the biotechnology company MOLOGEN AG has analyzed the survival times of patients enrolled in the study and the first data of the accompanying immunological tests. The...

The Management Board of MOLOGEN AG decided today with the agreement of the Supervisory Board to use the existing authorized capital 2011 in accordance with Para. 4 section 3 of the Articles of Association and to carry out a capital increase without...

The Japan Patent Office (JPO) has announced its decision to grant a patent to the biotechnology company MOLOGEN AG for its invention of an "allogeneic tumor therapy". This cancer therapy is based on allogeneic, genetically modified cancer...